The Chemical Heritage Foundation and the Biotechnology Industry Organization presented the 8th Annual Biotechnology Heritage Award to Alejandro Zaffaroni, PhD, a biotechnology pioneer and entrepreneur. The award was presented on April 10 at BIO 2006 in Chicago.

The global biotechnology industry earned record revenues in 2005 while moving toward profitability as it reduced its collective net losses.

FTC Plans to Study Competitive Impacts of Authorized Generic Drugs

Reverse Genetics Avian Influenza Vaccine Approved in France

GSK Begins Clinical Trials of Two H5N1 Vaccines

Company Notes for Apr. 6, 2006

Hubert J.P. Schoemaker and William T. McCormick. Perhaps we could have not a special day, but just a moment to remember what we owe and who we we owe it to.

Eisai plans $105-million plant. Novartis to build plant in China. BMS building $660-million biologics facility. Slow adoption of RFID. Vaccines update. $14.7 billion in pharma construction in 2006. Chiron sells Betaseron to Schering. Baxter to develop cell based H5N1 vaccine. Drug sales up 5.4%, but growth slowing.

Despite worries that industry is slow to adopt anticounterfeiting technologies, the 2006 Interphex program is rife with new methods for securing the supply chain.

Vitamin D and a sunny window shed som light on product stability.

No one is better than Europe when it comes to innovative products at the forefront of the industry

The right choice [of coding and marking technology] depends upon the company's top priorities regarding legibility, cost, speed, ease of use, cleanliness and security.

Once the brightest students are interested in bioprocessing, it is vital that they are prepared and inducted into industry.

Global Pharmaceutical Market Shows Moderate Growth

Vertex Pharmaceuticals? CEO Outlines Strategy for Growth

New Biodegradable Polyketals Developed for Drug Delivery

India and China Position for Growth in APIs

Progress Continues in Vaccine and Antiviral Development

GSK Begins RFID Pilot Program

Industry Leaders Call for New Paradigm in Drug Development

First GenerationNext Awards at Interphex 2006

BMS, Sanofi-Aventis Settle Over Generic Plavix

Spotlight on Products from Interphex

Actavis Makes $1.6 Billion Takevoer Bid for Pliva

Implementing a PAT Strategy

US Government Increase Orders for Flu Treatment from Roche, GSK

RFID and the Future of Pharmaceutical Supply Chains

Gottlieb Challenges Manufacturers to Make Processes More Efficient